37th EDRN Steering Committee Meeting/Prostate and Urological Cancers Collaborative Group Meeting Draft Agenda
Tuesday, October 19, 2021
10:00 a.m. – 5:00 p.m. Eastern Time
Chair : O. John Semmes, PhD, Eastern Virginia Medical School
Co-Chair: Martin Sanda, MD, Emory University School of Medicine
NCI Program Directors: Jacob Kagan, MSc, PhD, and Richard Mazurchuk, PhD, National Cancer Institute
Agenda
| 10:00 a.m. – 10:05 a.m. |
Welcome o O. John Semmes, PhD, East Virginia Medical School o Martin Sanda, MD, Emory University School of Medicine |
| 10:05 a.m. – 10:10 a.m. |
NCI Updates o Jacob Kagan, MSc, PhD National Cancer Institute o Richard Mazurchuk, PhD, National Cancer Institute |
| 10:10 a.m. – 10:25 a.m. |
01: Report from the Advocates Merel Grey Nissenberg, Esq., President, California Prostate Cancer Coalition |
| 10:25 a.m. – 11:15 a.m. | Team Projects and Projects (Supported with CORE Funds) |
|
o What was accomplished and what remains to be done o Feasibility of completion o Lessons learned o Recommendations for improvements |
|
| 10:25 a.m. – 10:45 a.m. | 02: P-MRI Study Update |
| John T. Wei, MD, University of Michigan | |
| 10:45 a.m. – 10:50 a.m. | Q&A |
| 10:50 a.m. – 11:10 a.m. |
03: The Prostate Upgrading Study o Phase 1: Robin Leach, PhD, The University of Texas Health Science Center San Antonio o Phase 2: Paul Boutros, PhD, MBA, Cancer Data Science, University of California, Los Angeles |
| 11:10 a.m. – 11:15 a.m. | |
| 11:15 a.m. – 11:25 a.m. | Break |
| 11:25 a.m. – 2:50 p.m. | Updates on GU Collaborative Group’s Studies |
| 11:25 a.m. – 11:45 a.m. |
04: Evolution of MyProstateScore (MPS): Urine transcriptomic analyses to detect aggressive prostate cancer Arul Chinnaiyan MD, PhD, University of Michigan |
| 11:45 a.m. – 11:50 a.m. | Q&A |
| 11:50 a.m. – 12:10 p.m. |
05: Glycoprotein Marker Panels for Aggressive Prostate Cancer Detection Hui Zhang, PhD, Johns Hopkins University School of Medicine |
| 12:10 p.m. – 12:15 p.m. | Q&A |
| 12:15 p.m. – 12:35 p.m. |
06: Proteomics Approaches to Detect Aggressive Prostate Cancers Thomas Kislinger, MSc, PhD, University of Toronto |
| 12:35 p.m. – 12:40 p.m. | Q&A |
| 12:40 p.m. – 1:00 p.m. |
07: Combining Serum Phi and Urine PCA3/T2Erg to Refine Patient Selection for Prostate Biopsy Martin Sanda, MD, Emory University |
| 1:00 p.m. – 1:05 p.m. | Q&A |
| 1:05 p.m. – 1:35 p.m. | Lunch Break |
| 1:35 p.m. – 1:55 p.m. |
08: Development of a Panel of Biomarkers for Aggressive Prostate Cancer Daniel W. Chan, PhD, Johns Hopkins University |
| 1:55 p.m. – 2:00 p.m. | Q&A |
| 2:00 p.m. – 2:20 p.m. |
09: Towards Early Prediction of Prostate Cancer Progression Applying Advanced Mass Spectrometry Technologies Tao Liu PhD Pacific Northwest National Laboratory |
| 2:20 p.m. – 2:25 p.m. | Q&A |
| 2:25 p.m. – 2:45 p.m |
10: CPDR-EDRN BRL: Dynamic Progress of Collaborative Biomarker Projects Gyorgy Petrovics, PhD, Center for Prostate Disease Research (CPDR) |
| 2:45 p.m. – 2:50 p.m. | Q&A |
| 2:50 p.m. – 3:00 p.m. | Break |
| 3:00 p.m. – 4:00 p.m. |
Discussion of Prostate Cancer Clinical Utility Study Moderator: Martin Sanda, MD, Emory University Discussants: o Yingye Zheng, PhD, Fred Hutchinson Cancer Research Center o Martin Sanda, MD, Emory University o Alan W. Partin, MD, PhD, Johns Hopkins University o Jeffrey Tosoian, MD, MPH, Vanderbilt University |
| 4:00 p.m. – 5:00 p.m. |
Summary and Open Discussion of the Current and Future Directions of the GU Collaborative Group O. John Semmes, PhD, East Virginia Medical School |
| 5:00 p.m. | Adjourn for the Day |